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Effects of Novel Calpain Inhibitors
in Transgenic Animal Model of
Parkinson’s disease/dementia with
Lewy bodies
Getaw Worku Hassen1,2, Leo Kesner1, Alfred Stracher1, Abraham Shulman3, Edward Rockenstein4,
Michael Mante4, Anthony Adame4, Cassia Overk4, Robert A. Rissman4 & Eliezer Masliah4,5
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders of
the aging population characterized by the accumulation of α-synuclein (α-syn). The mechanisms
triggering α-syn toxicity are not completely understood, however, c-terminus truncation of α-syn by
proteases such as calpain may have a role. Therefore, inhibition of calpain may be of value. The main
objective of this study was to evaluate the effects of systemically administered novel low molecular
weight calpain inhibitors on α-syn pathology in a transgenic mouse model. For this purpose, non-tg
and α-syn tg mice received the calpain inhibitors - Gabadur, Neurodur or a vehicle, twice a day for 30
days. Immunocytochemical analysis showed a 60% reduction in α-syn deposition using Gabadur and a
40% reduction using Neurodur with a concomitant reduction in c-terminus α-syn and improvements in
neurodegeneration. Western blot analysis showed a 77% decrease in α-spectrin breakdown products
(SBDPs) SBDPs with Gabadur and 63% reduction using Neurodur. There was a 65% reduction in the
active calpain form with Gabadur and a 45% reduction with Neurodur. Moreover, treatment with calpain
inhibitors improved activity performance of the α-syn tg mice. Taken together, this study suggests that
calpain inhibition might be considered in the treatment of synucleinopathies.
Parkinson’s disease (PD) and dementia with Lewy bodies are progressive neurological disorders of the aging population characterized by degeneration of dopaminergic and non-dopaminergic neurons associated with accumulation of α-synuclein (α-syn)1–4. The molecular mechanisms through which α-syn mediates neurodegeneration
in PD and DLB are poorly understood. While some studies have focused on understanding the toxic capabilities
of α-syn oligomers5,6, protofibrils and fibrils, more recent studies have advanced the possibility that cell to cell
transmission7 and prion-like seeded propagation of α-syn might have a major role8,9. Remarkably, among the
post-translational modifications involved in the pathogenesis of PD/DLB the c-terminus truncation of α-syn
(aa 116–121) has been shown to promote aggregation, propagation, and toxicity10. This truncation of α-syn can
be triggered by stress, physical activity and enzymatic cleavage by calpain and metaloproteases11–13. Calpain, a
ubiquitous cysteine protease found in the CNS, has been implicated in several neurodegenerative diseases including PD14,15. In PD and DLB levels of calpain expression and activity are elevated in the brain leading to synaptic
dysfunction and neuronal death13,16. Given the role of calpain in the disease process, its inhibition might represent
an appealing therapeutic option. In this study, we report the effects of two newly developed calpain inhibitors
(Gabadur and Neurodur) in a transgenic animal model of α-syn accumulation in PD/DLB. The advantage of
these 2 compounds compared to other calpain inhibitors is their ability to cross the blood-brain barrier (BBB)17.
In the case of Gabadur, this was achieved by combining the modified anti-seizure/pain medication Pregabalin as
a vehicle to cross the BBB and leupeptin as a calpain inhibitor. Whereas Neurodur was synthesized by attaching
the carboxyl group of cysteic acid to the leucyl-argininal of Leupeptin18. This enables Neurodur to use taurine
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Figure 1. Immunoblot analysis of the effects of calpain inhibitors on α-syn tg mice. α-Syn tg mice were
injected ip twice a day for 30 days with either Gabadur (1 mg/mouse; N = 10), Neurodur (1 mg/mouse; N = 10),
or PBS vehicle control (N = 10) and compared to vehicle-treated non-tg mice (N = 8). (a) Immunoblot and
(b) quantification of calpain levels. Calpain levels were significantly increased in vehicle-treated α-syn tg mice
compared to vehicle-treated non-tg mice. Treatment with either Gabadur or Neurodur significantly reduced
calpain protein levels in α-syn tg mice compared to vehicle-treated α-syn tg mice. (c) Immunoblot and (d)
quantification of α-spectrin breakdown products (α-SBDPs). α-SBDPs levels were significantly increased in
vehicle-treated α-syn tg mice compared to vehicle-treated non-tg mice. Treatment with either Gabadur or
Neurodur significantly reduced α-SBDPs protein levels in α-syn tg mice compared to vehicle-treated α-syn tg
mice. Statistical analysis was conducted using one-way ANOVA post hoc Dunnett’s test for comparison with
vehicle-treated non- tg mice (*p < 0.05) and Tukey–Kramer test for comparison with vehicle-treated α-syn tg
mice (#p < 0.05).

transporters to cross the BBB. Moreover, the carrier molecule taurine by itself has anti-inflammatory, calpain
inhibitory and calpastatin upregulatory effects18. We show that both calpain inhibitors reduced the accumulation
of α-syn and neurodegeneration in the hippocampus and the associated deficits. This study suggests that calpain
inhibition might be considered as a viable therapeutic target for synucleinopathies such as PD/DLB.

Results

Calpain inhibitors reduce α-syn pathology in the CNS of transgenic mice. Since in PD/DLB,
α-syn pathology and neurodegeneration has been associated with increased calpain activity, we wanted to test
if blocking this protease with two novel calpain inhibitor compounds that cross the BBB might ameliorate the
pathology. For this purpose α-syn, tg mice (n = 10 per group) were treated with either Gabadur or Neurodur
for 30 days at a dosage of 1 mg/mouse by IP injection twice a day and compared to vehicle-treated non-tg mice
(n = 8) to evaluate activity, neuropathology, and biochemistry. To verify target engagement using an indirect
method, brain homogenates were analyzed by immunoblot to assess the shift in calpain bands and SBDPs.
Compared to the non-tg mice, the vehicle-treated α-syn tg mice displayed a 33% increase in the calpain band at
78 kDa (Fig. 1a,b), in contrast, treatment with Gabadur or Neurodur reduced the 78 kDa calpain band by 45% and
35% respectively when compared to vehicle-treated α-syn tg mice (F = 13.75, p < 0.001) (Fig. 1a,b). Next, we analyzed by immunoblot α-spectrin which is known to be degraded by calpain in the CNS. Calpain, when activated,
degrades the 230-kDa subunit of the cytoskeletal protein α-spectrin to yield a 150-kDa calpain-cleaved breakdown fragment which was further degraded to a 145-kDa product. As expected, compared to the non-tg mice,
the vehicle-treated α-syn tg mice showed a 39% increase in SBDPs (Fig. 1c), whereas treatment with Gabadur
or Neurodur decreased SBDPs by 72% and 40%, respectively, when compared to vehicle-treated α-syn tg mice
(F = 31.95, p < 0.0001) (Fig. 1c).
When compared to the non-tg control, immunocytochemical analysis with an antibody against total α-syn
showed as expected in this line of α-syn tg mice extensive accumulation in the neuropil and neuronal cell bodies
in the deeper layers of the neocortex (Fig. 2a,b) and CA3 of the hippocampus (Fig. 2a,c). Treatment with Gabadur
or Neurodur resulted in 53% and 39% decreases, respectively, in the accumulation of α-syn in the neocortex
(F = 29.14, p < 0.0001) (Fig. 2a,b) when compared to vehicle-treated α-syn tg mice. Likewise, Gabadur reduced
α-syn aggregates in the hippocampus by 60% and Neurodur by 37% when compared to vehicle-treated α-syn tg
mice (F = 42.55, p < 0.0001) (Fig. 2a,c).
Since it has been proposed that among other mechanisms calpain might trigger pathology by cleaving α-syn
in the c-terminus10 we next analyzed the tissue sections with the SYN105 antibody that we have shown to recognize the α-syn cleaved at aa 11816. As expected no immunoreactivity was observed in the non-tg controls, in
contrast, vehicle-treated α-syn tg mice displayed considerably increased immunostaining of neuritic processes in
the neuropil and neuronal cell bodies in the deeper layers of the neocortex (Fig. 3a,b) and CA3 of the hippocampus (Fig. 3a,c). Treatment with Gabadur or Neurodur resulted in 35% and 38% decreases, respectively, in the
accumulation of c-terminus truncated α-syn in the neocortex (F = 69.76, p < 0.0001) (Fig. 3a,c) when compared
to vehicle-treated α-syn tg mice. Moreover, Gabadur and Neurodur reduced accumulation of c-terminally truncated α-syn in the hippocampus by 30% when compared to vehicle-treated α-syn tg mice (F = 66.82, p < 0.0001)
(Fig. 3a,c).
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Figure 2. Effects of Gabadur and Neurodur on total α-syn levels in the neocortex and hippocampus of α-syn
tg mice. α-Syn tg mice were injected ip twice a day for 30 days with either Gabadur (1 mg/mouse; N = 10),
Neurodur (1 mg/mouse; N = 10), or PBS vehicle control (N = 10) and compared to vehicle-treated non-tg mice
(N = 8). (a) Representative photomicrographs and quantitation of total α-syn immunoreactivity in the (b)
neocortex and (c) hippocampus. Immunoreactivity of total α-syn was significantly increased in vehicle-treated
α-syn tg mice compared to vehicle-treated non-tg mice in both the neocortex and hippocampus. Treatment
with either Gabadur or Neurodur significantly reduced total α-syn immunoreactivity in α-syn tg mice
compared to vehicle-treated α-syn tg mice. Scale bar = 35 µm. Statistical analysis was conducted using oneway ANOVA post hoc Dunnett’s test for comparison with vehicle-treated non- tg mice (*p < 0.05) and Tukey–
Kramer test for comparison with vehicle-treated α-syn tg mice (#p < 0.05).

Figure 3. Effects of Gabadur and Neurodur on c-terminus α-syn levels in the neocortex and hippocampus of
α-syn tg mice. α-Syn tg mice were injected ip twice a day for 30 days with either Gabadur (1 mg/mouse; N = 10),
Neurodur (1 mg/mouse; N = 10), or PBS vehicle control (N = 10) and compared to vehicle-treated non-tg
mice (N = 8). (a) Representative photomicrographs and quantitation of c-terminus α-syn immunoreactivity in
the (b) neocortex and (c) hippocampus. Immunoreactivity of c-terminus α-syn was significantly increased in
vehicle-treated α-syn tg mice compared to vehicle-treated non-tg mice in both the neocortex and hippocampus.
Treatment with either Gabadur or Neurodur significantly reduced c-terminus α-syn immunoreactivity in α-syn
tg mice compared to vehicle-treated α-syn tg mice. Scale bar = 35 µm. Statistical analysis was conducted using
one-way ANOVA post hoc Dunnett’s test for comparison with vehicle-treated non- tg mice (*p < 0.05) and
Tukey–Kramer test for comparison with vehicle-treated α-syn tg mice (#p < 0.05).

To confirm these findings using an independent approach, immunoblot analysis was performed. As expected,
in the cytosolic fraction, levels of total α-syn were increased in the tg mice compared to the vehicle-treated non-tg
controls (Fig. 4a,b). No differences were observed between the vehicle α-syn tg and the Gabadur-treated mice,
however, mice treated with Neurodur displayed increased soluble 14 kDa monomer band of α-syn (F = 36.85,
p < 0.001) (Fig. 4a,b). In the particulate fraction, the antibody against total α-syn identified α-syn as a band at
approximately 14 kDa in the non-tg mice. In vehicle-treated α-syn mice, this band had a 3-fold increase and the
presence of a smear at a higher molecular weight, probably representing oligomers, was also detected (Fig. 4c,d).
Treatment with Gabadur and Neurodur resulted in a reduction of the membrane α-syn low and higher molecular weight species by 35% when compared to vehicle-treated α-syn tg mice (F = 33.57, p < 0.0001) (Fig. 4c,d).
By western blot, c-terminally truncated α-syn was identified as a single band at 12 kDa in the vehicle α-syn tg
mice in the cytosolic (Fig. 4a,b) and membrane fractions (Fig. 4c,d), while no signal was detected in the non-tg
mice (Fig. 4a,c). Treatment with Gabadur and Neurodur reduced accumulation of c-terminally truncated α-syn
in the cytosolic (Fig. 4a,b) (F = 12.79, p = 0.002) and particulate fractions by approximately 35% and 65% when
compared to vehicle-treated α-syn tg mice (F = 18.75, p < 0.0001) (Fig. 4c,d).

Calpain inhibitors ameliorate α-syn mediated neurodegeneration and associated deficits in
the transgenic mice. We have previously shown that accumulation of full length and c-terminally truncated
α-syn results in neurodegeneration of the deeper layers of the neocortex and the CA3 region of the hippocampus
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Figure 4. Immunoblot analysis of the effects of Gabadur and Neurodur on total and C-terminus α-syn protein
levels in α-syn tg mice. α-Syn tg mice were injected ip twice a day for 30 days with either Gabadur (1 mg/
mouse; N = 10), Neurodur (1 mg/mouse; N = 10), or PBS vehicle control (N = 10) and compared to vehicletreated non-tg mice (N = 8). Hemibrains were homogenized and divided into cytosolic (soluble) and particulate
(membrane) fractions and analyzed by immunoblot. (a) Representative immunoblots of the cytosolic fraction
analyzed for total and c-terminus α-syn protein levels. (b) Quantitative analysis of total α-syn and c-terminus
α-syn protein levels. Total α-syn protein levels were significantly increased in vehicle-treated α-syn tg mice
compared to vehicle-treated non-tg mice. Treatment with either Gabadur or Neurodur increased total and
reduced c-terminus α-syn protein levels in α-syn tg mice compared to vehicle-treated α-syn tg mice. (c)
Representative immunoblots of the particulate fraction analyzed for total and c-terminus α-syn protein levels.
(d) Quantitative analysis of total α-syn and c-terminus α-syn protein levels. Treatment with either Gabadur or
Neurodur decreased total and c-terminus α-syn protein levels in α-syn tg mice compared to vehicle-treated
α-syn tg mice. Statistical analysis was conducted using one-way ANOVA post hoc Dunnett’s test for comparison
with vehicle-treated non- tg mice (*p < 0.05) and Tukey–Kramer test for comparison with vehicle-treated α-syn
tg mice (#p < 0.05).

Figure 5. Effects of Gabadur and Neurodur on neurodegeneration (NeuN) in the neocortex and hippocampus
of α-syn tg mice. α-Syn tg mice were injected ip twice a day for 30 days with either Gabadur (1 mg/mouse;
N = 10), Neurodur (1 mg/mouse; N = 10), or PBS vehicle control (N = 10) and compared to vehicle-treated
non-tg mice (N = 8). (a) Representative photomicrographs and quantitation of NeuN-positive neurons in
the (b) neocortex and (c) hippocampus. The number of NeuN-positive neurons was significantly reduced in
vehicle-treated α-syn tg mice compared to vehicle-treated non-tg mice in both the neocortex and hippocampus.
Treatment with either Gabadur or Neurodur significantly increased the number of NeuN-immunoreactive
neurons in both the neocortex and hippocampus. Scale bar = 35 µm. Statistical analysis was conducted using
one-way ANOVA post hoc Dunnett’s test for comparison with vehicle-treated non- tg mice (*p < 0.05) and
Tukey–Kramer test for comparison with vehicle-treated α-syn tg mice (#p < 0.05).

in this line of tg mice. When compared to the non-tg vehicle control, immunocytochemical analysis with an
antibody against the neuronal marker NeuN showed a 16% loss of neurons in the deeper layers of the neocortex (F = 8.147, p = 0.0003) (Fig. 5a,b) and 34% loss in the CA3 region of the hippocampus (Fig. 5a,c) in the
vehicle-treated α-syn tg mice. Treatment with Gabadur or Neurodur had no significant effects in the neocortex
(Fig. 5a,b) but ameliorated the loss of neurons in the CA3 region of the hippocampus (F = 13.88, p < 0.0001)
(Fig. 5a,c) when compared to vehicle-treated α-syn tg mice.
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Figure 6. Effects of Gabadur and Neurodur on astrogliosis and microgliosis in α-syn tg mice. α-Syn tg
mice were injected ip twice a day for 30 days with either Gabadur (1 mg/mouse; N = 10), Neurodur (1 mg/
mouse; N = 10), or PBS vehicle control (N = 10) and compared to vehicle-treated non-tg mice (N = 8). (a)
Representative photomicrographs and quantitation of GFAP-positive astrocytes in the (b) neocortex and (c)
hippocampus. The number of GFAP-positive neurons was significantly increased in vehicle-treated α-syn tg
mice compared to vehicle-treated non-tg mice in both the neocortex and hippocampus. Neither treatment with
Gabadur nor Neurodur significantly affected the number of GFAP-immunoreactive astrocytes in either the
neocortex or hippocampus compared to vehicle-treated α-syn tg mice. (d) Representative photomicrographs
and quantitation of Iba-1-positive microglia in the (e) neocortex and (f) hippocampus. The number of Iba1-positive microglia was significantly increased in vehicle-treated α-syn tg mice compared to vehicle-treated
non-tg mice in both the neocortex and hippocampus. Treatment with Gabadur or Neurodur significantly
reduced the number of Iba-1-immunoreactive microglia in the neocortex and hippocampus. Scale bar = 35 µm.
Statistical analysis was conducted using one-way ANOVA post hoc Dunnett’s test for comparison with vehicletreated non- tg mice (*p < 0.05) and Tukey–Kramer test for comparison with vehicle-treated α-syn tg mice
(#p < 0.05).

Next, we analyzed the effects of the calpain inhibitors on neuroinflammation. When compared to the non-tg
vehicle control, immunocytochemical analysis with an antibody against the astroglial marker GFAP showed a
25% increased in this marker in the deeper layers of the neocortex (F = 8.846, p = 0.002) (Fig. 6a,b) and a 15%
increase in the CA3 region of the hippocampus (F = 10.73, p = 0.0001) (Fig. 6a,c) in the vehicle-treated α-syn
tg mice. Treatment with Gabadur or Neurodur had no significant effects in the overall density of astroglial cells
neocortex (Fig. 6a,b) or the CA3 region of the hippocampus (Fig. 6a,c) when compared to vehicle-treated α-syn
tg mice; however, astroglial cells were less ramified in mice treated with Gabadur (p = 0.0003) or Neurodur
(p = 0.0007) compared to vehicle-treated α-syn tg mice (Fig. 6d). Immunocytochemical analysis with an antibody against the microglial marker Iba-1 showed a 19% increase in microgliosis in the neocortex (F = 19.38,
p < 0.001) (Fig. 6e,f) and 28% increase in the CA3 region of the hippocampus (F = 16.22, p < 0.001) (Fig. 6e,g)
in the vehicle-treated α-syn tg mice. Here, treatment with Gabadur (p < 0.0096) or Neurodur (P < 0.0001) significantly reduced the levels of microgliosis in the neocortex (Fig. 6e,f) and CA3 region of the hippocampus
(Fig. 6e,g) to levels comparable to the vehicle non-tg mice. Analysis of microglial cell ramifications showed a
significant increase in the vehicle-treated α-syn tg mice (F = 21.09, p < 0.001) (Fig. 6e,h) and treatment with
Gabadur (p < 0.0001) or Neurodur (P < 0.0001) significantly reduced the microglial cell ramifications (Fig. 6e,h)
to levels comparable to the vehicle non-tg mice.
Finally, we investigated the functional effects of the calpain inhibitors in the α-syn tg mice. Compared to the
non-tg mice the vehicle-treated α-syn tg mice showed a 45% increase in total activity in the open field (F = 13.75,
p = 0.0001) (Fig. 7a). Treatment with Gabadur or Neurodur ameliorated and normalized levels of activity to
those similar to non-tg controls (Fig. 7a). Other analysis in the open field including lateral movement, rearing,
and thigmotaxis did not show differences between non-tg and α-syn tg nor were there any changes with Gabadur
(p = 0.0001) or Neurodur (p = 0.0004) (Fig. 7b–d). This suggests that these compounds normalize the hyperactivity in the α-syn tg and that no side effects, such as anxiety, were observed.
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Figure 7. Effects of Gabadur and Neurodur on behavioral measures in α-syn tg mice. α-Syn tg mice were
injected ip twice a day for 30 days with either Gabadur (1 mg/mouse; N = 10), Neurodur (1 mg/mouse; N = 10),
or PBS vehicle control (N = 10) and compared to vehicle-treated non-tg mice (N = 8). Testing for (a) total
spontaneous locomotor activity, (b) lateral activity, (c) rearing, and (d) thigmotaxis. Compared to vehicletreated non-tg mice, vehicle-treated α-syn tg mice had a significant increase in total spontaneous activity.
Gabadur and Neurodur significantly reduced total spontaneous locomotor compared to vehicle-treated α-syn
tg mice. There were no significant differences between treatment groups in any of the other behavioral tests.
Statistical analysis was conducted using one-way ANOVA post hoc Dunnett’s test for comparison with vehicletreated non- tg mice (*p < 0.05) and Tukey–Kramer test for comparison with vehicle-treated α-syn tg mice
(#p < 0.05).

Discussion

The present study showed that similar to observations in PD/DLB patients, neurodegeneration is associated with
increased calpain fragments that indirectly suggest increased activity. Moreover, in a model of synucleinopathy,
CNS-penetrating calpain inhibitors reduced calpain, α-syn accumulation, and c-terminus truncation of α-syn,
while ameliorating neurodegenerative pathology in the hippocampus. In vitro and in situ experiments have
shown calpain cleaves α-syn, thereby affecting its metabolism and possibly leading to increased deposition19–21
and neurodegeneration. Therefore targeting calpain might be of benefit in patients with PD/DLB. In support of
the possibility that the neuroprotective effects of Gabadur and Neurodur are related to their effects on calpain,
we showed by immunoblot a reduction in the 78 kDa activated calpain band as well as decreased spectrin degradation. Moreover, we showed and suggested that the neuroprotective effects might be related to reductions
in α-syn cleavage at the c-terminus with a concomitant increase in total soluble monomeric α-syn. However, it
is worth noting that additional studies will be needed in the future to evaluate calpain activity with alternative
assays and more extensive analysis of various proteolytic fragments will be needed. It is possible that blocking
calpain and thus α-syn c-terminus truncation might be critical; however, a number of other substrates are cleaved
by calpain in the CNS and might co-participate in the neuroprotective mechanisms of these calpain blocking
compounds. These results are consistent with previous studies in acute and chemical models of PD. For example,
administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) increases calpain-mediated proteolysis
in nigral dopaminergic neurons in vivo15. Another indicator of the role of calpain in PD is that overexpression of
calpastatin leads to a reduction in truncated as well as aggregated α-syn22. In 1-methyl-4-Phenylpyridinium ion
(MPP+) treated granular neurons, calpain activation was increased by 74% as measured by SBDPs. Moreover,
these studies indicate that this cleavage is mediated by calpains and that MPP+ prompted an increase in cdk5
expression, as well as the cleavage of p35-p25, in a time-dependent manner. Studies in rodent and cell culture
models of PD suggest that treatment with calpain inhibitors (e.g., calpeptin, MDL-28170) can prevent neuronal
death23,24. Inhibition of calpain using calpain inhibitor (MDL-28170) or adenovirus-mediated overexpression
of the endogenous calpain inhibitor protein calpastatin, significantly attenuated MPTP-induced loss of nigral
dopamine neurons15.
Moreover, we have recently shown that overexpression of the calpain-specific inhibitor calpastatin reduces
α-syn processing, aggregation and synaptic impairment in A30P α-syn tg mice22. Together, these studies
support the crucial role of calpains, particularly of calpain 1, in the pathogenesis of PD and other synucleinopathies, supporting a potential therapeutical role of calpain inhibition in PD/DLB. Interestingly, calpain inhibition
has been shown to be neuroprotective in models of other neurological disorders such as Machado-Joseph disease25, and the superoxide dismutase 1 (SOD1) mutant (G93A) model of amyotrophic lateral sclerosis (ALS)26. It
was also found to reduce neurodegeneration of retinal ganglion cells in experimental optic neuritis27. Along these
lines, we found that despite some differences between them, Gabadur and Neurodur reduced calpain activity and
α-syn accumulation in the neocortex and hippocampus. This was accompanied by reduced neurodegeneration
and astrogliosis in the hippocampus and reduced microgliosis in the neocortex and hippocampus. This might be
related to the concentration of the compounds in the CNS and time of exposure. Another possible explanation for
this effect is that Gabadur might also exert its effects in the CNS via an α2-δ ligand of the voltage-gated calcium
channel which is upregulated in response to various insults28,29, thus probably targeting leucyl-argininal calpain
inhibitor to that site, unlike Neurodur which distributes everywhere in the CNS. Other limitations include the
sample size and the lack of more direct evidence for calpain inhibition in a time and dose-dependent fashion in
the CNS. Future studies will be needed to characterize in more detail the pharmacokinetic and pharmacodynamic
characteristics of Gabadur and Neurodur.
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In summary, we showed that treatment with the calpain inhibitors reduced α-syn related pathology and
improved activity performance of the α-syn tg mice. This suggests that targeting calpain might be a consideration
for the treatment of PD/DLB.

Materials and Methods

Animals. A total of 38 mice were utilized for this experiment; 8 non-tg controls and 30 (6-month-old) mice
over-expressing human wild-type α-syn under control of human Platelet-derived growth factor-β (h-PDGF-β)
promoter. This model was chosen because we have shown in similar models increased calpain activity and α-syn
cleavage resulting in aggregation and toxicity12. Furthermore, mice from this line develop α-syn aggregates distributed through neocortical and limbic brain regions similar to what has been described in DLB accompanied
by hyperactivity and learning behavioral deficits30.
Calpain inhibitors.

Two newly developed low molecular weight calpain inhibitors were tested. Gabadur:
composed of the active end of the calpain inhibitor, leupeptin (Acetyl-L-leucyl-L-leucyl-L–argininal) and linked
to stereochemically-modified Pregabalin. The latter is an analog of gamma-aminobutyric acid (GABA) that acts
as a carrier via a succinyl linker18,31. Its complete structure is [(3S,4S)-3 aminomethyl-4-amino-5-methyl hexanoic
acid]-Suc-Leu Arg-aldehyde l18,31–33. Pregabalin is an α2-δ ligand of the voltage-gated calcium channel similar to
GABA34–36. Gabadur utilizes Pregabalin to cross the blood-brain barrier (BBB) using L-type amino acid transporters and exerts its effect via α2-δ calcium channel subunit found on presynaptic sites of glutamatergic neurons28,37. A new study has further demonstrated the kinetics and ability to cross the BBB17. Neurodur is composed
of cysteic acid (α-amino-β-sulfo-propionic acid) that shares structural similarities with taurine. Neurodur utilizes
the Na+-dependent taurine transporters to cross the BBB as taurine31,33. Moreover, the carrier molecule taurine
by itself has anti-inflammatory, calpain-inhibitory, and calpastatin upregulatory effects. This is an additional benefit of Neurodur38–40. The combination of leupeptin and taurine has synergistic effects and is very appealing as a
therapeutic agent.
These combinations aim to rapidly target the drugs across the BBB as well as to the site of injury/pathology
to inhibit calpain and other proteases, while potentially decreasing high levels of calcium and neurotransmitters,
thereby conferring a dual therapeutic effect.

Treatments. Both Gabadur and Neurodur were prepared in phosphate buffer saline (PBS) 1X concentration
solution. Animals were injected intraperitoneally (IP) with Gabadur, Neurodur, or PBS twice a day (9 AM and
4 PM) for 30 days. The following groups were included: a) non-tg control mice vehicle-treated (n = 8); PDGFβα-syn tg mice vehicle-treated (n = 10); PDGFβ- α-syn tg mice Gabadur (30 mg/kg) treated (n = 10) and PDGFβα-syn tg mice Neurodur (30 mg/kg) treated (n = 10).
Tissue processing.

At the end of the 30-day treatment, the mice were sacrificed and the right hemibrains
were snap-frozen and stored at −70 °C for biochemical analysis, while the left hemibrains were fixed with 4%
paraformaldehyde for vibratome sectioning (50 µm) and neuropathological analysis. All animal procedures were
approved by the UCSD Institutional Animal Care and Use Committee under protocol #S02221. All methods were
performed in accordance with the relevant guidelines and regulations.

Immunoblot analysis of calpain and spectrin degradation. Calpain activity was measured indirectly
by analyzing the shift ratio of total vs active calpain bands (80 vs 78 kDa) and by ascertaining the substrate degradation using western blot analysis for SBDPs as previously described18. Calpain was detected using an anti-calpain
antibody (Dr. Naren Banik as a donation from Medical University of South Carolina), while α-spectrin was
detected with anti-spectrin α chain (nonerythroid) monoclonal antibody (EMD Millipore, Billerica, MA, USA)
(1:1000 dilutions). Actin (anti-β-actin; 1:1000 dilution; Sigma) was used as an internal control and for normalization of the image analysis. We used 1:2000 dilutions of the alkaline phosphatase-conjugated goat anti-rabbit
secondary antibody (Sigma, St. Louis, MO). Bands were visualized using 5-bromo-4-cholo-3- indoxyl-phosphate/
nitroblue tetrazolium Benzamidine (BCIP, Kirkegaard and Perry Labs, Gaithersburg, MD). Proteins were quantified using Image-pro plus 4.5.1 software (Media Cybernetics, Inc., Silver Spring, MD) and the results were
expressed in optical density units ± S.E.M.
Immunoblot analysis of α-syn in brain homogenates.

As previously described, brains were homogenized and divided into cytosolic (soluble) and particulate (membrane) fractions41. Briefly, brain samples from
the non-tg and tg mice treated with a vehicle, Gabadur or Neurodur (0.1 g) were homogenized in 0.7 ml of buffer
phosphatase and protease inhibitor cocktails (Calbiochem). Samples were centrifuged at 5,000 × g for five minutes at room temperature. Supernatants were retained and placed into appropriate ultra-centrifuge tubes and
centrifuged at 100,000 × g for one hour at 4 °C. This supernatant was collected, to serve as the cytosolic (soluble)
fraction, and the pellets were resuspended in 0.2 ml of buffer and re-homogenized; this was the particulate (membrane) fraction. The BCA protein assay was used to determine the protein concentration of the samples.
For immunoblot analysis, 20 µg of protein from the cytosolic or particulate fractions per lane was loaded into
4–12% Bis-Tris SDS-PAGE gels and blotted onto polyvinylidene fluoride (PVDF) membranes. For characterization of the effects of Neurodur and Gabadur on calpain c-terminus cleavage of -α-syn blots were probed with
the SYN105 antibody16 (1:1000), while effects of total -α-syn were evaluated with the SYN-1 antibody (mouse
monoclonal, 1:1000, BD Biosciences). Incubation with primary antibodies was followed by species-appropriate
incubation with secondary antibodies tagged with horseradish peroxidase (1:5000, Santa Cruz Biotechnology,
Santa Cruz, CA), visualization with enhanced chemiluminescence and analysis with a Versadoc XL imaging
apparatus (BioRad, Hercules, CA). Analysis of β-actin (Sigma, St. Louis, MO) levels was used as a loading control.
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Immunohistochemical and image analysis.

The procedure for immunohistochemical analysis has
been described elsewhere42. Briefly, blind-coded sagittal brain vibratome sections were treated at 4 °C for overnight with primary antibodies against α-syn (Syn-BD Biosciences)mouse monoclonal SYN105 antibody that
was raised to detect the C-terminally truncated- α-syn (aa 116–120). The characteristics and specificity of these
antibodies have been previously described16. This antibody was selected based on previous studies showing that
α-syn has a c-terminus domain sensitive to cleavage by calpain and other proteases43–45, the c-terminus truncated α-syn is more prone to aggregate and accumulate in the membrane fraction16,46, is more toxic47 and facilitates trans-cellular propagation12. To determine the effects on neuronal, astroglial and microglial cells sections
were incubated with primary antibodies against NeuN (Millipore, mouse monoclonal, 1:1000), GFAP (Millipore,
mouse monoclonal, 1:1000) and Iba-1 (Abcam, goat polyclonal, 1:500) respectively. Following overnight incubation, the sections were incubated with biotinylated secondary antibodies and detected with avidin D-HRP
(ABC Elite, Vector Laboratories, Burlingame, CA). To determine α-syn neuropathology (Syn-1 and SYN105)
and astrogliosis (GFAP), the brain sections were imaged by Olympus BX41microscope. The levels of immunoreactivity were determined by optical density analysis using Image Quant 1.43 program (NIH). From each section,
a total of 10 digital fields 1024 × 1024 pixels in the neocortex and hippocampus were analyzed. Levels of optical
density were corrected to the background using sections stained in the absence of the primary antibody. The
numbers of α-syn inclusion positive cells were determined per field (100 µm2). To estimate neuronal cell numbers briefly as previously described48, the numbers of NeuN-immunoreactive neurons in the hippocampus were
estimated utilizing unbiased stereological methods. The CA3 region of the hippocampus was outlined using an
Olympus BX51 microscope running StereoInvestigator 8.21.1 software (Micro-BrightField, Williston, VT) (grid
sizes 150 × 150 μm and the counting frames were 30 × 30 μm). The average coefficient of error for each region
was below 0.1. Sections were analyzed using a 100 × 1.4 PlanApo oil-immersion objective. The average mounted
tissue thickness allowed for 2 μm top and bottom guard-zones and a 5 μm high disector. To analyze microglial cell
morphology briefly as previously described49, sections labeled with Iba-1 were analyzed utilizing the Image-Pro
Plus program (Media Cybernetics, Silver Spring, MD) (10 digital images 1024 × 1024 pixels per section) and
analyzed in order to estimate the average number of microglial cells per unit area (100 μm2) and ramifications of
Iba-1 positive microglia50.

Statistical analysis. All analyses were performed using GraphPad Prism (version 5.0) software.

All experiments were done blind-coded and in triplicate. Values in the figures are expressed as means ± SEM.
To determine the statistical significance, values were compared using one-way analysis of variance (ANOVA) with
Dunnett’s post-hoc test when comparing non-tg vehicle control to the α-syn tg groups, while the Tukey-Krammer
posthoc test was used when comparing the α-syn tg vehicle vs the Gabadur or Neurodur groups as indicated in
each figure legend. The differences were considered to be significant if the p-values were less than 0.05.

Dataset Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding
author on reasonable request.
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